ZA925155B - Short term anti-cd3 stimulation of lymphocytes to increase their in vivo activity - Google Patents

Short term anti-cd3 stimulation of lymphocytes to increase their in vivo activity

Info

Publication number
ZA925155B
ZA925155B ZA925155A ZA925155A ZA925155B ZA 925155 B ZA925155 B ZA 925155B ZA 925155 A ZA925155 A ZA 925155A ZA 925155 A ZA925155 A ZA 925155A ZA 925155 B ZA925155 B ZA 925155B
Authority
ZA
South Africa
Prior art keywords
lymphocytes
stimulation
increase
short term
vivo activity
Prior art date
Application number
ZA925155A
Other languages
English (en)
Inventor
Augusto C Ochoa
C Ochoa Augusto
Cynthia Loeffler
Loeffler Cynthia
Walter Urba
Urba Walter
Dan L Longo
L Longo Dan
Original Assignee
C Ochoa Augusto
Loeffler Cynthia
Urba Walter
L Longo Dan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C Ochoa Augusto, Loeffler Cynthia, Urba Walter, L Longo Dan filed Critical C Ochoa Augusto
Publication of ZA925155B publication Critical patent/ZA925155B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
ZA925155A 1991-07-10 1992-07-10 Short term anti-cd3 stimulation of lymphocytes to increase their in vivo activity ZA925155B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72810791A 1991-07-10 1991-07-10

Publications (1)

Publication Number Publication Date
ZA925155B true ZA925155B (en) 1993-04-28

Family

ID=24925447

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA925155A ZA925155B (en) 1991-07-10 1992-07-10 Short term anti-cd3 stimulation of lymphocytes to increase their in vivo activity

Country Status (12)

Country Link
US (1) US5316763A (de)
EP (1) EP0593625B1 (de)
JP (1) JP3507489B2 (de)
AT (1) ATE142885T1 (de)
AU (1) AU674128B2 (de)
CA (1) CA2111564A1 (de)
DE (1) DE69213943T2 (de)
IE (1) IE922233A1 (de)
IL (1) IL102460A (de)
MX (1) MX9204077A (de)
WO (1) WO1993000918A1 (de)
ZA (1) ZA925155B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
ATE147633T1 (de) * 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
US5556763A (en) * 1992-04-06 1996-09-17 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Evaluation and treatment of patients with progressive immunosuppression
AU1524095A (en) * 1994-01-27 1995-08-15 Cellcor, Inc. Ex vivo activation of immune cells
WO1995032729A1 (en) * 1994-05-31 1995-12-07 Augusto Carlos Ochoa Short-term anti-cd3 stimulation of lymphocytes to increase their in vivo activity
US5723503A (en) * 1994-09-28 1998-03-03 Thomas Jefferson University Biological treatment for rheumatoid arthritis
US6033661A (en) 1995-06-07 2000-03-07 Thomas Jefferson University Composition and method for allogenetic mononuclear cell immunotherapy
WO1996040176A1 (en) * 1995-06-07 1996-12-19 Sloan-Kettering Institute For Cancer Research Therapeutic uses of monoclonal antibody ta99 in combination with interleukin-2 and/or lymphokine activated killer cells
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
PL328790A1 (en) * 1996-10-04 1999-02-15 Univ Jefferson T-lymphocytes provoking an immunological response and methods of using them
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
JP6074916B2 (ja) * 2012-05-22 2017-02-08 東洋製罐グループホールディングス株式会社 細胞活性化方法、及び細胞培養方法
CN107502589A (zh) * 2017-08-04 2017-12-22 北京世纪劲得生物技术有限公司 一种肿瘤浸润淋巴细胞与单个核细胞共培养方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0049611B2 (de) * 1980-10-02 1993-12-08 Hooper Trading Co. N.V. T-Zell-Wachstumsfaktor und Verfahren zu seiner Herstellung
US4464355A (en) * 1981-03-26 1984-08-07 Hooper Trading Co. Serum-free and mitogen-free T-cell growth factor and process for making same
US4683199A (en) * 1983-01-31 1987-07-28 Sloan-Kettering Institute For Cancer Research Interleukin-2 dependent cytotoxic T-cell clones
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8405555D0 (en) * 1984-03-02 1984-04-04 Rees A D M Macrophage activating factors
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
DE3687014T2 (de) * 1985-05-01 1993-04-01 Asahi Chemical Ind Zum erkennen von tumoren faehige klonierte t-zelle und ein t-zellen-antigenrezeptor.
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
WO1988000970A2 (en) * 1986-08-08 1988-02-11 Regents Of The University Of Minnesota Method of culturing leukocytes
US4808151A (en) * 1987-04-27 1989-02-28 E. I. Du Pont De Nemours And Company Simplified method for the preparation of human lymphokine activated killer cells
US4882424A (en) * 1987-05-11 1989-11-21 Dana-Farber Cancer Institute, Inc. Activation antigen
AU2925789A (en) * 1987-12-17 1989-07-19 Browning's Clinical Pathology Services Limited Lymphokine activation of cells for adoptive immunotherapy, e.g. of hiv infection
FI105320B (fi) * 1988-04-04 2000-07-31 Oncogen Menetelmä vasta-aineheterokonjugaattien valmistamiseksi, joita käytetään imusoluaktiivisuuden säätelyssä ja diagnoosissa
EP0409901A4 (en) * 1988-04-15 1991-10-30 Research Corporation Technologies, Inc Lak cell cytotoxin
WO1990004633A1 (en) * 1988-10-21 1990-05-03 Brigham And Women's Hospital ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR
ATE147633T1 (de) * 1988-10-27 1997-02-15 Univ Minnesota Immunhilfsmittel aus liposome enthaltend lymphokin il -2
GR1001034B (el) * 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
US5126132A (en) * 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer

Also Published As

Publication number Publication date
MX9204077A (es) 1994-06-30
AU674128B2 (en) 1996-12-12
IL102460A0 (en) 1993-01-14
JP3507489B2 (ja) 2004-03-15
EP0593625A4 (de) 1994-11-02
AU2300592A (en) 1993-02-11
JPH07502486A (ja) 1995-03-16
EP0593625A1 (de) 1994-04-27
EP0593625B1 (de) 1996-09-18
DE69213943T2 (de) 1997-04-10
US5316763A (en) 1994-05-31
IE922233A1 (en) 1993-01-13
WO1993000918A1 (en) 1993-01-21
IL102460A (en) 2001-08-26
DE69213943D1 (de) 1996-10-24
ATE142885T1 (de) 1996-10-15
CA2111564A1 (en) 1993-01-21

Similar Documents

Publication Publication Date Title
ZA925155B (en) Short term anti-cd3 stimulation of lymphocytes to increase their in vivo activity
Fischer et al. Granulocyte-macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function.
ATE246513T1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
GR3023975T3 (en) Peripheralization of hematopoietic stem cells.
GR3032660T3 (en) Lymphokine gene therapy of cancer.
MX9304800A (es) Glicoformas novedosas del receptor complemento soluble tipo 1.
GB1499035A (en) Antistaphylococcus human immune globulin and method of preparing same
IL74156A (en) Method for the preparation of a monoclonal antibody and of an immortalized cell producing the same and pharmaceutical compositions containing the monoclonal antibody
AU2112288A (en) Method and dosage form using an antagonist to gamma interferon to control MHC-associated autoimmune disease
Nagai et al. Antitumor effects on mouse melanoma elicited by local secretion of interleukin-12 and their enhancement by treatment with interleukin-18
EP0902783A4 (de)
HUT63769A (en) Process for producing pharmaceutical compositions comprising il-4 as active ingredient and suitable for treating thick tumours
RU93042874A (ru) Соединения полипептидной природы, способ их получения, композиция на их основе, их применение в противоопухолевой терапии
Diamantstein et al. Stimulation of B-cells by dextran sulphate in vitro
NZ224116A (en) Compositions of interleukin-2 and fk565; method of stimulation of the immune system and package
OA09863A (en) Use of IL-4 to enhance immune response to immunogens in vaccines.
Holmberg Effect on electrically induced convulsions of the number of previous treatments in a series
EP0227809A4 (de) Verfahren und zusammensetzung zur behandlung von krebs und nichtmalignen tumoren.
EP0631474A4 (en) Cyclic anti-tumor promoter compounds, compositions and methods for production and use.
GR3031785T3 (en) Antitumor Vaccines Comprising IL-6 Transfected Cells.
DE69433110D1 (de) Allogenes vakzin und synthesemethode für selbiges
TW372873B (en) A novel anti-neoplastic cytokine
Scheibenbogen et al. Phase II study of intermittent low-dose IFN-gamma in metastatic renal cell cancer
Flemming et al. SARCOMA CELLS ENGINEERED TO SECRETE IFN-γ OR IL-2 ACQUIRE SENSITIZATION TO IMMUNE CELL KILLING VIA DIFFERENT MECHANISMS
Whiteside The natural killer (NK) cell and synergistic antitumor effects of interferon-gamma and interleukin-2